



Toshkent tibbiyot akademiyasi Urganch filiali “Jamoat salomatligi va umumiy gigiyena” kafedrasini mudiri, Ibadulla Qochkarovich Abdullayevning 70 yilligiga bag‘ishlangan “Sog‘liqni saqlash tizimida menejmentning zamonaviy muammolari va istiqbollari” mavzusidagi xalqaro ilmiy-amaliy anjuman 2025-yil 20-21 oktabr

BRONXIAL ASTMA BILAN KASALLANGAN BEMORLARDA KLINIKO-ANAMNESTIK KO‘RSATKICHLARINI VA XAVF OMILLARINI O‘RGANISH



¹Satliqov Rashid Karimovich

²Abdullayev Ravshan Bobojonovich

³Ziyadullayev Shuxrat Xudayberdiyevich

⁴Xamidova Gulnoz Sayfidinovna <https://orcid.org/0000-0001-6404-9792>
gulnozhamidova440@gmail.com kontakt.telefon 937535661

¹TTA Urganch filiali xarbiy dala terapiyasi va gemotologiya kafedrasini mudiri ²TTA Urganch filiali ichki kasalliklar, nefrologiya, gemodializ va reabilitologiya kafedrasini professori D.Sc.

³O‘zbekiston Respublikasi Fanlar Akademiyasi Immunologiya va inson genomikasi instituti ilmiy ishlar bo‘yicha direktor o‘rinbosori, professor D.Sc.

⁴TTA Urganch filiali ichki kasalliklar, nefrologiya, gemodializ va reabilitologiya kafedrasini katta o‘qituvchisi, PhD.

Annotatsiya Ushbu maqolada bronxial astma bilan og‘rigan bemorlarda tashqi xavf omillari va anamnez asosiy klinik simptomlarni bo‘yicha statistik ma‘lumotlar va xalqaro markazlarning ilmiy tadqiqotlari natijalari keltirilgan.

Kalit so‘zlar: nafas qisilishi, gemoptiz, obstruksiya, bronxial shilliq qavatning shikastlanishi.
ИССЛЕДОВАНИЕ КЛИНИКО-АНАМНЕСТИЧЕСКИХ ПОКАЗАТЕЛЕЙ И ФАКТОРОВ РИСКА У БОЛЬНЫХ БРОНХИАЛЬНОЙ АСТМОЙ

¹Сатликов Рашид Каримович к.м.н

²Абдуллаев Равшан Бобожонович д.м.н

³Зиядуллаев Шухрат Худайбердиевич д.м.н

⁴Хамидова Гульназ Сайфиidinovна <https://orcid.org/0000-0001-6404-9792>
gulnozhamidova440@gmail.com kontakt.telefon 937535661

¹Заведующий кафедрой военно-полевой терапии и гематологии Ургенчского филиала

²профессор кафедры внутренних болезней, нефрологии, гемодиализа и реабилитологии Ургенчского филиала

³заместитель директора по научной работе Института иммунологии и геномики человека Академии наук Республики Узбекистан

⁴старший преподаватель кафедры внутренних болезней, нефрологии, гемодиализа и реабилитологии Ургенчского филиала .

Аннотация: В данной статье представлены статистические данные и результаты научных исследований международных центров по внешним факторам риска и основным клиническим симптомам в анамнезе у больных бронхиальной астмой.

Ключевые слова: одышка, кровохарканье, обструкция, повреждение слизистой оболочки бронхов.



Toshkent tibbiyot akademiyasi Urganch filiali “Jamoat salomatligi va umumiy gigiyena” kafedrasi mudiri, Ibadulla Qochkarovich Abdullayevning 70 yilligiga bag‘ishlangan “Sog‘liqni saqlash tizimida menejmentning zamonaviy muammolari va istiqbollari” mavzusidagi xalqaro ilmiy-amaliy anjuman 2025-yil 20-21 oktabr

STUDY OF CLINICAL AND ANAMNESTIC INDICATORS AND RISK FACTORS IN PATIENTS WITH BRONCHIAL ASTHMA

¹Satliqov Rashid Karimovich. Head of the Department of "VPT and Hematology"

²Abdullayev Ravshan Bobojonovich. Urgench Branch of the Department of Internal Diseases, Nephrology, Hemodialysis and Rehabilitation, D.Sc.

³Ziyadullayev Shukhrat Khudayberdiyevich. Vice-Rector for Research, Professor, D.Sc., Institute of Immunology and Human Genomics, Academy of Sciences of the Republic of Uzbekistan

⁴Khamidova Gulnoz Sayfidinovna. Urgench Branch of the Department of Internal Diseases, Nephrology, Hemodialysis and Rehabilitation

Abstract: This article presents statistical data and the results of scientific research conducted by international centers on external risk factors and the main clinical symptoms in the medical history of patients with bronchial asthma.

Key words: dyspnea, hemoptysis, obstruction, bronchial mucosal damage.

Chronic bronchitis. Bronchial asthma is a widespread chronic respiratory disease characterised by inflammation of the airways, reversible airway obstruction and bronchospasm. It affects people of all ages and significantly impacts quality of life and healthcare systems worldwide. The prevalence of bronchial asthma varies considerably by region. In developed regions such as North America and Europe, prevalence is approximately 10% of the population. This high rate is partly associated with lifestyle factors such as increased awareness, improved diagnostic capabilities, and exposure to indoor allergens. Conversely, in developing countries in Asia and Africa, the prevalence is lower, typically ranging from 2 to 4%. Rapid urbanisation and lifestyle changes are leading to an increase in asthma cases in these regions.

In Latin America, a variety of patterns of disease spread are observed: in some countries, the indicators are comparable to those of developed countries. There is also a significant difference in the prevalence of asthma between urban and rural areas. Higher rates have been recorded in cities, which is associated with factors such as increased air pollution and the diversity of allergen exposure. This urban-rural disparity illustrates the impact of environmental factors on the spread of asthma. Another important genetic factor contributing to asthma susceptibility is related to the regulation of immunoglobulin E (IgE) levels. IgE is an antibody that plays a central role in allergic responses. It has been found that certain genetic variants affect the production of IgE and the response to it, which in turn influences the likelihood of developing allergic reactions closely associated with asthma. For example, polymorphisms in the gene encoding the β -chain of the high-affinity IgE receptor (Fc ϵ RI- β) have been found to be associated with increased IgE levels and a higher risk of asthma. In addition, recent genome-wide association studies (GWAS) have identified numerous other genes related to asthma. These genes are involved in regulating the tone of airway smooth muscles, controlling mucus secretion, and maintaining epithelial integrity — all of which play a crucial role in the pathogenesis of asthma. For example, the ORMDL3 gene located on chromosome 17q21 has been repeatedly identified as a risk factor for asthma in various populations. These gene variants are believed to influence the risk of developing asthma by regulating inflammation in the airways[8].

Research objective. The indicators of statistical data on external risk factors and history based on the main clinical symptoms were studied in 120 patients suffering from bronchial asthma.

Research methods and materials. The study involved 120 patients with a history of bronchial asthma in the pulmonology department of VKTTM. The patients were divided into 3 groups: the first group included 60 patients with BA and pulmonary hypertension, the second group included 60 patients with BA without pulmonary hypertension, and the third control group included 30 healthy individuals. Groups were selected randomly. The study was conducted with the consent of the



Toshkent tibbiyot akademiyasi Urganch filiali “Jamoat salomatligi va umumiy gigiyena” kafedrası mudiri, Ibadulla Qochkarovich Abdullayevning 70 yilligiga bag‘ishlangan “Sog‘liqni saqlash tizimida menejmentning zamonaviy muammolari va istiqbollari” mavzusidagi xalqaro ilmiy-amaliy anjuman 2025-yil 20-21 oktabr

participants. Results: The leading symptoms and risk factor indicators in the patients included in the study were examined. The parameters measured in the examined patients were analysed in 3 groups. The results of the indicator analysis are presented in Table 1.

Clinical-anamnestic indicators and risk factors of BA patients and control group indicators

According to the summary analysis results, patients in group 1 had an average age of 58.1 ± 6.3 years,

	1-Patients with BA + pulmonary hypertension, (n=60)	2--patients without BA + pulmonary hypertension in group, (n=60)	3-control group (n=30)
Average age (years)	$58,1 \pm 6,3$	$53,5 \pm 7,6$	$47,1 \pm 5,9$
Gains (E/A, abs. %)	31 (53,3%) / 28 (46,7%)	26 (43,3%) / 34 (56,7%)	14 (46,7%) / 16 (53,3%)
Smoking	41 (67,1%)	35 (56,9%)	4 (13,3%)
Impact on air pollution (Aral Sea region factors)	45 (74,2%)	37 (61,0%)	6 (20,0%)
Weather and living conditions factors	31 (50,5%)	24 (40,0%)	5 (16,7%)
Occupational hazards (manufacturing, agriculture, etc.)	19 (31,0%)	17 (25,9%)	3 (10,0%)
Genetic predisposition (family history)	13 (19,7%)	8 (13,3%)	2 (6,7%)
Associated comorbid conditions (hypertension, CHD, diabetes mellitus)	37 (60,5%)	22 (37,1%)	4 (13,3%)
Average duration (years of illness)	$12,3 \pm 4,5$	$8,6 \pm 3,8$	—
Severity of clinical signs (dyspnoea ≥ 2 points on the MRC scale)	43 (71,0%)	28 (46,7%)	—

which was found to be higher than in group 2 (53.5 ± 7.6 years) and the control group (47.1 ± 5.9 years). In terms of gender composition, the proportion of men among patients with pulmonary hypertension (53.3%) was higher than that of women, which may primarily be associated with tobacco smoking. When comparing risk factors, tobacco smoking was 66.7% in group 1, 56.7% in group 2, and only 13.3% in the control group. Additionally, environmental factors, specifically atmospheric pollution and dust exposure in the Aral Sea region, showed high figures among patients. Air pollution occurred in 74.2% in group 1, 61.0% in group 2, and 20.0% in the control group. Risk factors related to dust and home conditions were also higher in group 1 (50.5%) and showed a significant difference compared to the control group (16.7%). Occupational hazards (harmful effects in the fields of industry and agriculture) were identified in 31.0% of Group 1, 25.9% of Group 2, and 10.0% of healthy individuals. Although genetic predisposition had a relatively low value, it was recorded higher in both patient groups compared to the control group. Analysis of comorbid diseases showed that they occurred in 60.5% of cases in Group 1, 37.1% in Group 2, and only 13.3% in the control group. Particularly, arterial hypertension and diabetes mellitus were more common in the group with pulmonary hypertension. At the same time, the severity of dyspnoea also differed: dyspnoea of ≥ 2 points on the MRC scale was observed in 70.0% of patients in Group 1 and 46.7% in Group 2. These data indicate that patients with BA complicated by pulmonary hypertension tend to



Toshkent tibbiyot akademiyasi Urganch filiali “Jamoat salomatligi va umumiy gigiyena” kafedrasi mudiri, Ibadulla Qochkarovich Abdullayevning 70 yilligiga bag‘ishlangan “Sog‘liqni saqlash tizimida menejmentning zamonaviy muammolari va istiqbollari” mavzusidagi xalqaro ilmiy-amaliy anjuman 2025-yil 20-21 oktabr

be older and have a higher cluster of risk factors (especially smoking, air pollution, and comorbid diseases). This condition may serve as an additional factor in the development of pulmonary hypertension and can lead to a worsening of clinical symptoms.

LITERATURE:

1. Сулейманова, ДН; Рахманова, УУ; Сатликов, РК; ,ОСОБЕННОСТИ ИММУНОЛОГИЧЕСКИХ МАРКЕРОВ У ПАЦИЕНТОВ С β -ТАЛАССЕМИЕЙ, Замонавий клиник лаборатор ташхиси долзарб муаммолари,,1,160-161,2022,
2. Исанова, ДТ; Самандарова, БС; Юлдашев, НБ; Сатликов, РК; ,Клинико-микробиологическое значение изучения аутомикрофлоры кожи у женщин фертильного возраста, VA ESTETIK TIBBIYOT,,46,2013,
3. Сатликов, РК; ,Микробиологические особенности и антимикробная резистентность при неосложненных инфекциях мочевых путей, Дисс... к. м. н.,,2008,
4. Сатликов, РК; Юлдашев, БС; Закиров, ШЮ; Каримов, РХ; ИЗУЧЕНИЯ, М; ,ИНФЕКЦИЯХ МОЧЕВЫХ ПУТЕЙ, Монография: -Т.: “O‘ZKITOBSAVDONASHRIYOTI” NMIU, 84,,2022,
5. Сотликов Рашид Каримович, Хамидова Гулноз Сайфиддиновна; ,ОСОБЕННОСТИ ОРГАНИЗАЦИИ ОБУЧЕНИЯ ИНОСТРАННЫХ СТУДЕНТОВ В УРГЕНЧЕСКОМ ФИЛИАЛЕ ТАШКЕНТСКОЙ МЕДИЦИНСКОЙ АКАДЕМИИ, ИНТЕРИОРИЗАЦИЯ ПРОФЕССИОНАЛЬНЫХ ЦЕННОСТЕЙ: ВОПРОСЫ ОБУЧЕНИЯ ИНОСТРАННЫХ СТУДЕНТОВ, 1,1,216,2024, "Издательство ВолГМУ, 2024"
6. Satlikov, RK; ,FEATURES OF THE CLINICAL COURSE OF PRIMARY IMMUNE THROMBOCYTOPENIA,"FARS International Journal of Education, Social Science & Humanities.",13,5,611-615,2025,
7. Satlikov, RK; ,SEASONAL CHARACTERISTICS AND RISK FACTORS FOR THE DEVELOPMENT OF IMMUNE THROMBOCYTOPENIA,"ZAMONAVIY TA'LIM TIZIMINI RIVOJLANTIRISH VA UNGA QARATILGAN KREATIV G'OYALAR, TAKLIFLAR VA YECHIMLAR",8,79,202-205,2025,
8. Perkins T. N. [и др.]. RAGE -dependent VCAM -1 expression in the lung endothelium mediates IL -33-induced allergic airway inflammation // Allergy. 2019. № 1 (74). С. 89–99.
9. Principe S. [и др.]. Treating severe asthma: Targeting the IL-5 pathway // Clinical & Experimental Allergy. 2021. № 8 (51). С. 992–1005.
10. Qibin L. [и др.]. The impact of PM2. 5 on lung function in adults with asthma // The International Journal of Tuberculosis and Lung Disease. 2020. № 6 (24). С. 570–576.
11. Ramonell R. P., Iftikhar I. H. Effect of anti-IL5, anti-IL5R, anti-IL13 therapy on asthma exacerbations: a network meta-analysis // Lung. 2020. (198). С. 95–103.
12. Sadek E. [и др.]. Efficacy and safety of liquorice extract in patients with bronchial asthma: a randomized controlled trial // Indian J. Public Health Res. Dev. 2020. (11). С. 585–590.
13. Sakamoto T., Hizawa N. Genetics in Asthma Respiratory Disease Series: Diagnostic Tools and Disease Managements / под ред. А. Yokoyama, Singapore: Springer Singapore, 2019. С. 3–14.
14. Soliai M. M. [и др.]. Multi-omics colocalization with genome-wide association studies reveals a context-specific genetic mechanism at a childhood onset asthma risk locus // Genome Medicine. 2021. № 1 (13). С. 157.